New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 14, 2014
11:46 EDTRPTP, RAX, GOGO, OLED, UBNT, MNKD, ICPT, CALL, ARWR, VNDAOptions with decreasing implied volatility
Options with decreasing implied volatility: RPTP ARWR CALL ICPT MNKD UBNT OLED GOGO RAX UVXY VNDA
News For RPTP;ARWR;CALL;ICPT;MNKD;UBNT;OLED;GOGO;RAX;VNDA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 10, 2014
12:11 EDTARWROptions with increasing implied volatility
Subscribe for More Information
October 9, 2014
11:00 EDTARWROptions with increasing implied volatility
Options with increasing implied volatility: ARWR PBR EXXI PWE GST GLNG WTW AFSI ETE VALE
10:00 EDTARWROn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:03 EDTICPTIntercept pullback a buying opportunity, says Summer Street
Subscribe for More Information
09:02 EDTRAXRackspace appoints Brian Kelly as Chief Security Officer
Rackspace announced the appointment of Brian Kelly as Chief Security Officer. Kelly will be responsible for overseeing physical and information security efforts for Rackspace and its customers globally. Prior to Rackspace, Kelly served as Ernst & Young's Executive Director where he successfully modernized and transformed enterprise security programs while driving business value.
08:38 EDTARWRArrowhead price target lowered to $12 from $24 at Piper Jaffray
Subscribe for More Information
08:33 EDTARWRArrowhead issues letter to shareholders regarding ARC-520
Subscribe for More Information
06:18 EDTARWRArrowhead downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital downgraded Arrowhead to Sector Perform citing low-end efficacy in the AASLD abstract. Price target lowered to $9.
05:50 EDTARWRStocks with implied volatility movement; ARWR TKMR
Stocks with implied volatility movement; Arrowhead (ARWR) 158, Tekmira (TKMR) 130 according to iVolatility.
October 8, 2014
16:26 EDTARWROn The Fly: Closing Wrap
Subscribe for More Information
13:12 EDTARWRArrowhead risk/reward favorable, says Deutsche Bank
Subscribe for More Information
12:42 EDTICPTIntercept weakness a buying opportunity, says Wedbush
Subscribe for More Information
12:11 EDTICPTIntercept management to meet with Oppenheimer
Subscribe for More Information
11:48 EDTARWRArrowhead sell-off overdone, long-term view unchanged, says Jefferies
Subscribe for More Information
11:10 EDTARWROptions with increasing implied volatility
Subscribe for More Information
10:55 EDTARWRArrowhead ARC-520 treatment effect much lower than expected, TheStreet says
Subscribe for More Information
10:46 EDTARWRArrowhead plunges after HepB data abstract posted
Subscribe for More Information
09:20 EDTICPTOn The Fly: Pre-market Movers
Subscribe for More Information
07:05 EDTICPTIntercept says FLINT trial NASH data will not be presented at AASLD
Intercept Pharmaceuticals announced upcoming presentations of data at the upcoming American Academy for the Study of Liver Diseases, or AASLD, Annual Meeting, being held in Boston, Massachusetts from November 7-11. Obeticholic acid, or OCA, Intercept's lead product candidate, is a bile acid analog and first-in-class agonist of the farnesoid X receptor in development for primary biliary cirrhosis, nonalcoholic steatohepatitis, primary sclerosing cholangitis and other chronic liver and intestinal diseases. CEO Mark Pruzanski said, "We are pleased that several key abstracts from Intercept's Phase 3 program for OCA in PBC will be presented at AASLD. With respect to the NIDDK-sponsored FLINT trial of OCA in NASH, we have learned that the NASH CRN has decided to focus on finalizing the manuscript intended for near term publication in lieu of presentation at AASLD. We are reaffirming the previously reported top-line results based on a revised draft manuscript that our partners at NIDDK have provided us. We believe that peer reviewed publication of the FLINT data will mark another important milestone supportive of OCA's potential as a novel therapy for patients with NASH and associated liver fibrosis. In the meantime, we continue preparing for the initiation of our Phase 3 NASH program in the first half of 2015."
05:53 EDTMNKDStocks with implied volatility movement; MNKD AFSI
Stocks with implied volatility movement; MannKind (MNKD) 85, AmTrust Financial (AFSI) 68 according to iVolatility.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use